Betuvax-CoV-2
A new method for creating antitussive vaccines with nanoparticles has been patented
Irina Nevinnaya, Rossiyskaya Gazeta
A patent for a new method of creating a coronavirus vaccine using spherical nanoparticles was obtained by a subsidiary of the Human Stem Cell Institute. We are talking about a subunit recombinant vaccine of the new generation "Betuvax-CoV-2". It contains spherical nanoparticles that mimic viral particles and contain a surface antigen (protein) of the coronavirus. Currently, the company is awaiting permission from the Ministry of Health to conduct clinical trials, the HSCC reported today.
This type of vaccine refers to subunit vaccines. They contain only surface antigens of the coronavirus, which makes it possible to reduce the protein content in the drug and, consequently, reduce its allergenicity (the ability to cause undesirable reactions). As a result, subunit vaccines are better tolerated compared to other drugs and less likely to cause side effects, which is especially important for their use in risk groups. In addition, such drugs have good prospects when used for repeated vaccinations. The design of the new vaccine, its creators note, also makes it possible, if necessary, to quickly optimize the drug taking into account emerging new strains of coronavirus.
"The patent for the use of spherical nanoparticles is an important part of the development of a vaccine for the prevention of COVID–19," explained Alexander Kudryavtsev, one of the vaccine developers. – With the help of these particles, 100-300 nm in size, similarity with the virus is achieved. Antigens are immobilized on them – surface proteins of the coronavirus, to which the body produces antibodies. Our vaccine is a kind of coronavirus model for immunity training. The results of preclinical animal studies have shown that immunity trained on such virus-like particles destroys the virus before any symptoms appear. We took a very large dose for infection, so the protection turned out to be, as they say, "with a margin."
Another great advantage of vaccines of this type is that they are easy to scale. "If desired, it is possible to set up production in the required quantities for billions of doses in a matter of months," Alexander Kudryavtsev believes.
Portal "Eternal youth" http://vechnayamolodost.ru